Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Mind Medicine Inc (MNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: MNMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $24.5
1 Year Target Price $24.5
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 21.99% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 534.92M USD | Price to earnings Ratio - | 1Y Target Price 24.5 |
Price to earnings Ratio - | 1Y Target Price 24.5 | ||
Volume (30-day avg) 11 | Beta 2.88 | 52 Weeks Range 4.70 - 10.44 | Updated Date 07/3/2025 |
52 Weeks Range 4.70 - 10.44 | Updated Date 07/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.84% | Return on Equity (TTM) -37.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 345267655 | Price to Sales(TTM) - |
Enterprise Value 345267655 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.57 | Shares Outstanding 75553296 | Shares Floating 70711057 |
Shares Outstanding 75553296 | Shares Floating 70711057 | ||
Percent Insiders 0.85 | Percent Institutions 55.18 |
Upturn AI SWOT
Mind Medicine Inc
Company Overview
History and Background
Mind Medicine (MindMed) Inc. was founded in 2019. It's a biotechnology company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies to address addiction and mental health. It went public in 2020 and has pursued clinical trials and partnerships to advance its pipeline.
Core Business Areas
- Drug Development: Developing novel psychedelic-inspired therapeutics for psychiatric disorders and substance abuse.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of its drug candidates.
Leadership and Structure
Robert Barrow is the CEO. The company has a structured management team overseeing drug development, clinical operations, and business strategy. They have a Board of Directors that manages overall governance and strategic direction.
Top Products and Market Share
Key Offerings
- MM-120 (Lysergide D-Tartrate): MM-120 is MindMed's lead drug candidate, a synthetic form of LSD being developed for Generalized Anxiety Disorder (GAD). It's currently in Phase 2b trials. Market share data is not currently available as it is pre-commercialization. Competitors include companies developing treatments for GAD and other mental health disorders. These treatments include SSRIs, SNRIs, and traditional therapeutic options.
- MM-402: MM-402 is an R-enantiomer of MDMA, being developed as a potential treatment for autism spectrum disorder (ASD). It aims to offer the positive effects of MDMA, such as increased sociability, without the potential negative effects. It is pre-clinical and has no market share or revenues. Potential competitors are companies that develop medicines or therapies for autism spectrum disorder, which is largely a non-pharmaceutical treatment market currently.
Market Dynamics
Industry Overview
The psychedelic medicine industry is an emerging field focused on developing therapies based on psychedelic compounds for mental health and addiction. It is attracting increasing investment and regulatory interest.
Positioning
MindMed is a key player in the psychedelic medicine industry, focusing on rigorous clinical trials and drug development. It aims to differentiate itself through scientific validation and regulatory approval of its products.
Total Addressable Market (TAM)
The TAM for mental health treatments, including anxiety, depression, and addiction, is estimated to be billions of dollars annually. MindMed is positioned to capture a share of this market if its therapies are approved and successfully commercialized.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio
- Experienced leadership team
- Focus on rigorous clinical trials
- Early mover advantage in the psychedelic medicine industry
Weaknesses
- High cash burn rate
- Dependence on regulatory approvals
- Limited revenue stream
- Relatively new company with limited historical performance data
Opportunities
- Growing acceptance of psychedelic therapies
- Potential for breakthrough therapies for unmet medical needs
- Strategic partnerships with pharmaceutical companies
- Expansion into new indications and markets
Threats
- Regulatory hurdles and uncertainty
- Competition from other companies in the psychedelic medicine industry
- Potential for adverse events in clinical trials
- Negative public perception of psychedelics
Competitors and Market Share
Key Competitors
- ATAI
- COMP
Competitive Landscape
MindMed competes with other biotech companies focused on psychedelic-assisted therapies. The competitive landscape is characterized by a race to secure intellectual property, advance clinical trials, and obtain regulatory approvals. As a pre-revenue company, it is very difficult to calculate market share. All companies in the field are trying to create their individual markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is represented by advancement of drugs through clinical trial phases and partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates. Analyst estimates vary widely due to the uncertain nature of the industry.
Recent Initiatives: Recent initiatives include the initiation and continuation of clinical trials for MM-120 and MM-402, and partnerships with academic institutions.
Summary
MindMed is a high-risk, high-reward biotechnology company operating in the emerging psychedelic medicine industry. Its success depends on the successful completion of clinical trials and regulatory approvals. The company needs to manage its cash burn rate effectively and capitalize on opportunities to establish a strong market position. Competition and regulatory hurdles remain significant challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MindMed Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. The psychedelic medicine industry is highly speculative, and investments are subject to significant risk. Market Share is difficult to calculate because the market is pre-commercialization.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mind Medicine Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-03-03 | CEO & Director Mr. Robert Barrow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.mindmed.co |
Full time employees 74 | Website https://www.mindmed.co | ||
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.